reports
CohBar Reports Second Quarter 2023 Financial Results
CohBar Reports Second Quarter 2023 Financial Results MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. (“Morphogenesis”), for an all-stock transaction to advance a late-stage oncology pipeline. The c...
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Ph...
Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores ...
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract f...
Morphogenesis, Inc. and CohBar, Inc. Announce Acceptance of Abstract for Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. (“Morphogenesis”), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ: CWBR) (“CohBar”), today announced that Morphogenesis’ abstract has been accepted for poster prese...
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agre...
CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merge...
CohBar Reports Third Quarter 2022 Financial Results and Highlights Rec...
CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress Conference call and webcast today at 5:00 p.m. ET, November 8, 2022 MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. “I’m plea...
CohBar to Announce 2022 Third Quarter Financial Results and Provide Bu...
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022 Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2...
CohBar Announces Reverse Stock Split
CohBar Announces Reverse Stock Split MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced that its Board of Directors (the “Board”) has approved a 1-for-30 reverse stock split of the company’s common stock. The reverse stock split will become effective at 12:01am ET on September 23, 2022 and begin trading on a split-adjusted basis at th...
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Con...
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022. H.C. Wainwright 24th...
CohBar Reports Second Quarter 2022 Financial Results and Highlights Re...
CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress IND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the second quarter ended June 30, 2022 and highl...
CohBar to Announce 2022 Second Quarter Financial Results and Provide B...
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022 Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 second quarter financial results after the market closes on Monday, August 15, 20...
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors
CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company’s Board, effective July 11, 2022. Dr. Tozzo brings extensive research and development experience at both established pharmaceutical and innovativ...
CohBar to Participate at Upcoming Conferences in June 2022
CohBar to Participate at Upcoming Conferences in June 2022 MENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will participate at two upcoming conferences. BIO International Convention – June 13-16, 2022 June 14th at 5:00 pm PT, San Diego, CA The presentation may be accessed via we...
CohBar to Present at the H.C. Wainwright Global Investment Conference
CohBar to Present at the H.C. Wainwright Global Investment Conference MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today its virtual participation in the 2022 H.C. Wainwright Global Investment Conference. Dr. Joseph Sarret, CohBar’s Chief Executive Officer, will present a company overview available for on-demand listening starting Tue...
CohBar Reports First Quarter 2022 Financial Results and Highlights Rec...
CohBar Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress Conference call and webcast today at 5:00 p.m. ET, May 16, 2022 MENLO PARK, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress. “I am optimistic abo...
CohBar Announces Extension of Nasdaq Compliance Period and Summarizes ...
CohBar Announces Extension of Nasdaq Compliance Period and Summarizes 2022 Annual Meeting Proposal MENLO PARK, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced that The Nasdaq Capital Market has granted the Company’s request for a 180 day extension, or until November 7, 2022, of the period to regain compliance with its minimum bid...
CohBar to Announce 2022 First Quarter Financial Results and Provide Bu...
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022 Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 first quarter financial results after the market closes on Monday, May 16, 2022. Manag...
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and...
CohBar Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update Conference call and webcast at 5:00 p.m. ET today, March 29, 2022 MENLO PARK, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “202...
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results...
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022 Company to host conference call and webcast at 5:00 p.m. ET MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2021 fourth quarter and full year financial results after the market clo...
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
CohBar to Present at H.C. Wainwright BIOCONNECT Conference MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright BIOCONNECT Conference, being held virtually January 10 - 14, 2022. H.C. Wainwright BIOCONNECT Conference ...
CohBar Announces Changes to its Board of Directors and R&D Leadership
CohBar Announces Changes to its Board of Directors and R&D Leadership Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBar’s founders Drs. Nir Barzilai, Pinchas Cohen,...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.